{"id":"W1534401608","doi":"10.1016/s1470-2045(15)70137-3","title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Epirubicin; Docetaxel; Clinical endpoint; Bevacizumab; Breast cancer; Internal medicine; Cyclophosphamide; Chemotherapy; Oncology; Fluorouracil; Neoadjuvant therapy; Mucositis; Phases of clinical research; Clinical trial; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006727463,0.0003091225,0.0009485048,0.00002651399,0.0001375817,0.00003442569,0.0004926153,0.0001433825,0.00001658597],"category_scores_gemma":[0.0001278678,0.0002007791,0.00003426469,0.0001273197,0.0002635563,0.00001975113,0.0001981537,0.0001046388,0.000002066601],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001733397,"about_ca_system_score_gemma":0.0004385541,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009414062,"about_ca_topic_score_gemma":0.0007274644,"domain_scores_codex":[0.9981462,0.0002797605,0.0003548218,0.0005409812,0.0001609834,0.0005172025],"domain_scores_gemma":[0.9984997,0.0002031907,0.0002943818,0.000481863,0.0002676893,0.0002531988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.921384,0.0015803,0.0003780049,0.00002243564,0.000893209,0.000005822188,0.002970686,0.00002039371,0.03239346,0.00002226964,0.01786431,0.02246509],"study_design_scores_gemma":[0.9257311,0.0250224,0.002321914,0.00004124158,0.0002811348,0.00004528826,0.0008831137,0.00001223926,0.02014857,0.0001359172,0.0249596,0.0004175148],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910595,0.0007582425,0.0001113523,0.003397323,0.0001913239,0.003066464,0.001047463,0.00001734723,0.0003510049],"genre_scores_gemma":[0.9941027,0.0002551318,0.001094751,0.000880626,0.0005478752,0.002648619,0.00008467717,0.00004330807,0.0003423453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0234421,"threshold_uncertainty_score":0.8187533,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04623737131073502,"score_gpt":0.3696223259041013,"score_spread":0.3233849545933662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}